BG Medicine Goes Public, Begins Trading at $7 per Share | GenomeWeb

BG Medicine this week began trading shares of its stock on the Nasdaq under the ticker symbol "BGMD."

The diagnostics firm is offering 5 million shares of its stock at $7 per share, with a target of $35 million in total proceeds – roughly 41 percent of the $86.3 million target the company gave when it filed to go public a year ago and 52 percent of the adjusted $67 million target it set in November (PM 12/03/2010).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.

It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.

A proposed bill would require NSF to only fund research that's in "the national interest."

Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.